Top Stories
The investment comes about two years since the UK pharma last committed $800 million to build out its manufacturing capabilities in the state.
The Japanese drugmaker gained Hovilpri (pritelivir) in its €780-million takeout of Aicuris earlier this year.
If the biotech prices at the high end of its proposed range, its valuation could reach close to $1 billion.
Weltruza, the company's new formulation of olanzapine, needs no loading doses or oral supplementation.
The drugmaker said it tested Chai's models across a panel of diverse targets and saw designs with "strong binding affinities."
Conference News
HONG KONG, Oct. 10, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase III clinical study (COMPASSION-40/AK104-313) evalua...
- In an independent, propensity score-matched analysis of 2,684 individuals living with ATTR-CM from Epic COSMOS, the largest U.S. electronic health record database, acoramidis was associated with a s...
HIGH POINT, N.C., Oct. 10, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.(Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1...
NEW YORK, Oct. 10, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-imp...
New analyses on Furoscix ReadyFlow PK/PD performance delivered via an autoinjector demonstrated comparable urine output to IV furosemideConsistent bioavailability, diuresis and natriuresis across inj...
